Skip to content
Buy This GLP
← Research
Safety

Are GLP-1 Drugs Banned in Sport? WADA Rules for 2026 and 2027

WADA monitors semaglutide and tirzepatide. Investigational drugs are subject to separate rules, including the S0 rule for unapproved substances.

Editorial profile: Wesley JenkinsBuy This GLP Editorial Team4 min read
Where weight-loss peptides stand in sport, 2026Semaglutide and tirzepatideboth included in WADA monitoringLiraglutideabsent from the 2026 Prohibited ListInvestigational drugscheck the S0 rule and ask your anti-doping organizationThe Prohibited List is revised every year. Check the current list.

The current rules for approved medicines

As of November 14, 2026, WADA does not prohibit semaglutide, tirzepatide, or liraglutide. The agency monitors semaglutide and tirzepatide in and out of competition to track potential patterns of misuse. The published 2027 program continues monitoring both drugs.[1][2][3][4]

Investigational drugs require a separate check

The retatrutide approval and trial guide explains why an investigational drug falls into a different regulatory situation. WADA’s S0 category prohibits pharmacological substances without approval for human therapeutic use when they are not covered by another category. A substance can fall under S0 without being named. Ask your anti-doping organization to confirm the status of any investigational product.[1][3][5]

What the studies measured

Weight change alone cannot tell an athlete how a medicine will affect training or performance. Research on lean mass during GLP-1 treatment explains what body-composition studies can measure. A 2026 narrative review found no consistent evidence of a performance benefit in humans.[6]

Check the exact medicine with your anti-doping organization before competition. Use the WADA list in force on the event date, and tell your prescriber that you compete under anti-doping rules.

Frequently asked

Are semaglutide or tirzepatide banned in sport?
WADA includes both in its 2026 and published 2027 Monitoring Programs for in- and out-of-competition monitoring. Check which rules apply to the event you are entering.
What if an investigational drug is absent from the list by name?
WADA’s S0 category covers substances with no current approval for human therapeutic use when no other section applies. Confirm your specific product with your anti-doping organization.

Sources

  1. [1] World Anti-Doping Agency (2026). The 2026 Prohibited List WADA. Source
  2. [2] World Anti-Doping Agency (2026). The 2026 Monitoring Program WADA. Source
  3. [3] World Anti-Doping Agency (2027). The 2027 Prohibited List WADA. Source
  4. [4] World Anti-Doping Agency (2027). The 2027 Monitoring Program WADA. Source
  5. [5] U.S. Food and Drug Administration (2026). FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss FDA. Source
  6. [6] La Vignera S, Condorelli RA (2026). Incretin-Based Therapies in Sports: Pharmacological Mechanisms, Performance-Enhancing Potential, and Anti-Doping Implications—A Narrative Review International Journal of Molecular Sciences. PMID 42511463

More in Safety